We are leaders, innovators and entrepreneurs working together to redefine the way medicines are made.

Executive Team

Chief Executive Officer and Director

team Karen Anderson

Chief People Officer

Chief Technology and Quality Officer

Chief Administrative Officer

April Dovholuk

Senior Vice President Development Operations

General Counsel

Ellie Im

Senior Vice President Clinical Development, Oncology

harris rotman headshot grayscale

Senior Vice President
Regulatory Affairs

Senior Vice President
IR and Corporate Communications

Chief Financial Officer

team patrick yue

Senior Vice President
Clinical Development, Innovative Medicines

Chairman of Development

Board of Directors

Francesco De Rubertis, PhD

Chairman of the Board, Centessa Pharmaceuticals
Co-Founder & Partner, Medicxi

Read Bio

Francesco De Rubertis, PhD

Chairman of the Board, Centessa Pharmaceuticals
Co-Founder & Partner, Medicxi

Read Bio

Arjun Goyal, MD, MPHIL, MBA

Co-Founder and Managing Director Vida Ventures

Read Bio

Arjun Goyal, MD, MPHIL, MBA

Co-Founder and Managing Director Vida Ventures

Read Bio

Mary Lynne Hedley, PhD

Senior Fellow and Strategic Advisor The Broad Institute of M.I.T. and Harvard

Read Bio

Mary Lynne Hedley, PhD

Senior Fellow and Strategic Advisor The Broad Institute of M.I.T. and Harvard

Read Bio

Mathias Hukkelhoven, PhD

Former Senior Vice President, Global Regulatory, Safety & Biometrics Bristol Myers Squibb (BMS)

Read Bio

Mathias Hukkelhoven, PhD

Former Senior Vice President, Global Regulatory, Safety & Biometrics Bristol Myers Squibb (BMS)

Read Bio

Samarth Kulkarni, PhD

Chief Executive Officer
CRISPR Therapeutics

Read Bio

Samarth Kulkarni, PhD

Chief Executive Officer
CRISPR Therapeutics

Read Bio

Saurabh Saha, MD, PhD

Chief Executive Officer


Read Bio

Saurabh Saha, MD, PhD

Chief Executive Officer


Read Bio

Carol Stuckley, MBA

Former Pfizer Inc.
Corporate Officer

Read Bio

Carol Stuckley, MBA

Former Pfizer Inc.
Corporate Officer

Read Bio

Brett Zbar, MD

Managing Director and Global Head of Life Sciences
General Atlantic

Read Bio

Brett Zbar, MD

Managing Director and Global Head of Life Sciences
General Atlantic

Read Bio

Our mission is to discover and develop medicines that are truly transformational for patients through our medical research

Scroll to Top
;
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B